Excellent Outcomes for the First Sirolimus Eluting Balloon Tested on Instent Restesosis

Much has been done since studies on conventional balloon angioplasty for BMS instent restenosis showed over 40% new revascularization. 

El primer balón liberador de sirolimus probado en reestenosis intrastent demostró excelentes resultados

Drug eluting stents, aimed at improving this problem, have never achieved 0% restenosis, which is why technologies such as paclitaxel coated balloons have been developed, with reasonable efficacy (8% to 10% reinterventions rate for BMS restenosis and 17% to 23% for DES restenosis).

 

Paclitaxel is less effective against restenosis than the Limus family of drugs, but it offers the advantage of rapid diffusion in tissues, which is key in drug coated balloons.


Read also: An Important Study Shows That Renal Function Must Be Cared for in TAVR”.


The sirolimus eluting balloon Virtue solved the problem by encapsulating the drug into nanoparticles, which rapidly transferred through the porous balloon. This prevents drug waste, which is the case of paclitaxel balloons.

 

This is the first in human trial with this new device, to assess, basically, feasibility. It included 50 patients with restenosis with angiographic 6 month and clinical 12 month follow up.

 

Primary efficacy end point at 6 months was late lumen loss, which resulted in 0.31±0.52 mm, and secondary end point was binary restenosis, which reached 19.1%.


Read also: Bioresorbable Scaffolds Must Not Be Chosen Over Current DES”.


At one year, target vessel failure was 12.2% for the intention to treat population and 2.8% for the per-protocol population.

 

Conclusion

The first in human trial of the sirolimus eluting balloon Virtue showed excellent outcomes, which guarantees future randomized studies.

 

Editorial Comment

The great difference in target vessel failure in the intention to treat population vs. per- protocol population was due to major protocol violations that excluded 14 patients out of the total 50.

 

Original title: The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis) Angiographic Results and 1-Year Clinical Outcomes.

Refrerence: Stefan Verheye et al. J Am Coll Cardiol Intv 2017. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...